Enovis Q1 Earnings Call Highlights
MarketBeat
Enovis (NYSE:ENOV) reported a solid start to 2026, with management pointing to share gains in its reconstructive surgery business, stable growth in prevention and recovery, and continued investment in new products including ARVIS and Nebula.
On the company’s first-quarter earnings call, Chief Execu
NYSE:ENOV